Sign In

Michael Scannell

Sr. Director, CMC Development at Esperion - The Lipid Management Company

Michael Scannell is a pharmaceutical executive with extensive experience in chemistry, manufacturing, and controls (CMC) development. He served as Senior Director of CMC Development at Esperion - The Lipid Management Company from December 2019 to January 2022, where he oversaw critical aspects of drug product development and regulatory compliance.12

Currently, he holds the position of Vice President, Chemistry and CMC at Longboard Pharmaceuticals, a role he has been in since March 2023. His career spans over two decades, with leadership roles at companies like United Therapeutics and SCYNEXIS, focusing on analytical sciences, manufacturing strategy, and regulatory submissions.1

Michael earned a Ph.D. in Chemistry from the University of Maryland College Park and a Bachelor's degree in Chemistry from Towson University.1

Highlights

Mar 17 · tcw.com
[PDF] 3M Co. Annual Meeting Agenda (05/12/2020) 1 Elect Thomas K ...

Related Questions

What are Michael Scannell's main responsibilities at Esperion?
How long has Michael Scannell been in the pharmaceutical industry?
What is Michael Scannell's educational background?
What are some of Michael Scannell's notable achievements in his career?
How did Michael Scannell transition from United Therapeutics to Esperion?
Michael Scannell
Michael Scannell, photo 1
Michael Scannell, photo 2
Add to my network

Location

Raleigh-Durham, North Carolina Area